| Issue |
Med Sci (Paris)
Volume 28, Number 1, Janvier 2012
|
|
|---|---|---|
| Page(s) | 37 - 38 | |
| Section | Nouvelles | |
| DOI | https://doi.org/10.1051/medsci/2012281013 | |
| Published online | 27 January 2012 | |
Nouvelle thérapie antiangiogénique indépendante du VEGF qui cible le récepteur CD160
A novel VEGF-independent antiangiogenic therapy targeting the CD160 receptor
1
Inserm UMR 1043, CNRS UMR 5282, université de Toulouse, centre de physiopathologie de Toulouse-Purpan, hôpital Purpan, Bât. A, BP 3028, 31024 Toulouse Cedex 3, France
2
Institut Jean Godinot, BP171, 51056 Reims Cedex, France
3
Inserm UMR 976, pavillon Bazin, hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
*
philippe.le-bouteiller@inserm.fr
**
armand.bensussan@inserm.fr
Cet article ne possède pas de résumé.
© 2012 médecine/sciences – Inserm / SRMS
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.
